Home › Research › Laboratory science
Human iPSC 4R tauopathy model uncovers modifiers of tau propagation
Parra Bravo C, Giani AM, Madero-Perez J, Zhao Z, Wan Y, Samelson AJ, Wong MY, Evangelisti A, Cordes E, Fan L, Ye P, Zhu D, et al.. Cell, 2024-04-05
Topic: Brain proteins, microglia and lab models
Plain-language summary
Tauopathies are age-associated neurodegenerative diseases whose mechanistic underpinnings remain elusive, partially due to a lack of appropriate human models. Here, we engineered human induced pluripotent stem cell (hiPSC)-derived neuronal lines to express 4R Tau and 4R Tau carrying the P301S MAPT mutation when differentiated into neurons. 4R-P301S neurons display progressive Tau inclusions upon seeding with Tau fibrils and recapitulate features of tauopathy phenotypes including shared transcriptomic signatures, autophagic body accumulation, and reduced neuronal activity. A CRISPRi screen of genes associated with Tau pathobiology identified over 500 genetic modifiers of seeding-induced Tau propagation, including retromer VPS29 and genes in the UFMylation cascade. In progressive supranuclear palsy (PSP) and Alzheimer's Disease (AD) brains, the UFMylation cascade is altered in neurofibrillary-tangle-bearing neurons. Inhibiting the UFMylation cascade in vitro and in vivo suppressed seeding-induced Tau propagation. This model provides a robust platform to identify novel therapeutic strategies for 4R tauopathy.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Parra Bravo, C., Giani, A. M., Madero-Perez, J., Zhao, Z., Wan, Y., Samelson, A. J., et al. (2024). Human iPSC 4R tauopathy model uncovers modifiers of tau propagation. Cell. https://doi.org/10.1016/j.cell.2024.03.015
Vancouver
Parra Bravo C, Giani AM, Madero-Perez J, Zhao Z, Wan Y, Samelson AJ, et al. Human iPSC 4R tauopathy model uncovers modifiers of tau propagation. Cell. 2024. doi:10.1016/j.cell.2024.03.015. PMID: 38582079.
BibTeX
@article{parrabravo2024-38582079,
author = {Parra Bravo, C. and Giani, A. M. and Madero-Perez, J. and Zhao, Z. and Wan, Y. and Samelson, A. J. and Wong, M. Y. and Evangelisti, A. and Cordes, E. and Fan, L. and Ye, P. and Zhu, D. and others},
title = {{Human iPSC 4R tauopathy model uncovers modifiers of tau propagation}},
journal = {Cell},
year = {2024},
doi = {10.1016/j.cell.2024.03.015},
pmid = {38582079},
url = {https://doi.org/10.1016/j.cell.2024.03.015}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A CRISPRi screen of genes associated with Tau pathobiology identified over 500 genetic modifiers of seeding-induced Tau propagation, including retromer VPS29 and genes in the UFMylation cascade.
Why it matters
Using human induced pluripotent stem cell-derived neurons expressing 4R Tau and 4R-P301S Tau, this study identified over 500 genetic modifiers of seeding-induced tau propagation, including retromer VPS29 and genes in the UFMylation cascade, and found the UFMylation cascade altered in tangle-bearing neurons in progressive supranuclear palsy and Alzheimer's disease brains. Inhibiting the UFMylation cascade suppressed tau propagation in vitro and in vivo, but this is a laboratory model providing a platform for identifying strategies rather than a proven treatment.
Study details
- Evidence strengthEarly
Limitations
The platform cannot recapitulate features of aged human neurons; it expresses only 4R tau with the FTD-linked P301S mutation, so it models 4R tauopathy rather than Alzheimer's 3R/4R tauopathy; it lacks other cell types such as microglia that modify tau spread; and long-term consequences of sustained UFMylation inhibition are not understood.
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 53 of the 98 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cell) |
| Journal's citation record | 4 / 4 | Cell: journal h-index 1,220 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “ipsc”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 80 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 19.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 80 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Li Gan: h-index 71 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38582079) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 53 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 53 of the 98 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Laboratory science from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.